Mizuho Securities Reaffirms Their Buy Rating on Xeris Pharmaceuticals Inc (XERS)


Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS) today and set a price target of $27. The company’s shares closed yesterday at $20.43.

Yang noted:

“We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.7% and a 48.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals Inc with a $28 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.98 and a one-year low of $15.75. Currently, Xeris Pharmaceuticals Inc has an average volume of 84.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company. It offers XeriSol™ and XeriJect™ formulation technologies. The firm focuses on the development of patient-friendly injectable drugs to address unmet medical needs. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts